Cognitive Reserve-building Activities in Multiple Sclerosis
Cognitive Reserve-building Activities in Multiple Sclerosis: a Randomized Controlled Trial of the Effect of Cognitive Leisure Activities on Objective and Subjective Measures of Cognition
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Cognitive Leisure Activities
What it measured
Main measures
Change in score on the Symbol Digit Modality Test (SDMT)
Baseline, week 12, week 24
Thinking and memoryChange in score on the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ)
Baseline, week 12, week 24
Thinking and memory
Other measures (5)
Change in score on the California Verbal Learning Test II (CVLT II)
Baseline, week 12, week 24
Thinking and memoryChange in score on the Brief Visuospatial Memory Test Revised (BVMT-R)
Baseline, week 12, week 24
Thinking and memoryChange in score on the Word Fluency Test (phonological)
Baseline, week 12, week 24
Change in score on the Five-point Test
Baseline, week 12, week 24
Change in score on the Cognitive Leisure and Activity Scale (CLAS)
Baseline, week 12, week 24, week 36
Thinking and memory
Who could take part
Relapsing and progressive · 18 to 65
Show the full criteria
Inclusion criteria
* RRMS, SPMS or PPMS * Age 18-65 * EDSS score ≤ 6.5 * SDMT (or PASAT) score below -1 SD * No depression based on the MDI * Able to use computer or smartphone and has internet access * If in treatment with one or more of the following medications, the dosage must be stable: * Cannabinoids * Anticholinergic medications * Sedatives e.g., benzodiazepines * Opioids * Antispasmodics * Beta-blockers * Antidepressant medication * Fampridine
Exclusion criteria
* Planned start-up or discontinuation of one or more of the above-mentioned medications * Structural brain changes following previous head trauma or neurological conditions other than which lead to structural changes or affect cognitive abilities * Epilepsy * Significant psychiatric co-morbidity * Significant somatic co-morbidity including, but not limited to, severe cardiovascular disease as well as liver, kidney, and endocrine diseases * Relapse 3 months prior to inclusion
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The study is a crossover randomized controlled trial investigating the effect of increasing engagement in cognitive leisure activities for individuals with multiple sclerosis.
Papers
Results
Cognitively stimulating activities in multiple sclerosis: Results of a randomized controlled trial.Mult Scler Relat Disord · 2026
Loading reviews and guidelines…
History
Started
Dec 2022
Main results due
Nov 2024
Finished
Feb 2025